BCR-complex-specific antibodies and methods of using same
This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
1. A method of altering B cell function in a subject, comprising administering to said subject a therapeutically effective amount of a molecule that binds human BCR complex, wherein said molecule is an antibody or an antigen-binding fragment thereof, a diabody, or a polypeptide, and wherein said molecule comprises:
(I) the amino acid sequence of an immunoglobulin light chain variable region (V L ) that is a humanized variant of BCC V L that comprises:
(A) a modification at Kabat residue 37;
(B) a modification at Kabat residue 45; or
(C) both (A) and (B);
and
(II) the amino acid sequence of an immunoglobulin heavy chain variable region (V H ) that is a humanized variant of BCC V H that comprises a modification of one or more of Kabat residues 48, 62, 66, 67, 68, 69, 70, 71 or 73.
2. The method of claim 1 , wherein said V L has:
(A) a leucine substitution at Kabat residue 37;
(B) a lysine or an asparagine substitution at Kabat residue 45; or
(C) both (A) and (B).
3. The method of claim 1 , wherein said V L has an asparagine substitution at Kabat residue 45.
4. The method of claim 1 , wherein said V L comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20.
5. The method of claim 4 , wherein said V L comprises the amino acid sequence of SEQ ID NO:16.
6. The method of claim 1 , wherein said V H comprises one or more modifications selected from the group consisting of:
(A) an isoleucine substitution at Kabat residue 48;
(B) a lysine substitution at Kabat residue 62;
(C) a lysine substitution at Kabat residue 66;
(D) an alanine substitution at Kabat residue 67;
(E) a leucine substitution at Kabat residue 69;
(F) a valine substitution at Kabat residue 71; and
(G) a lysine substitution at Kabat residue 73.
7. The method of claim 1 , wherein said V H comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:36.
8. The method of claim 7 , wherein said V H comprises the amino acid sequence of SEQ ID NO:34.
9. The method of claim 1 , wherein:
(I) said V L comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20; and
(II) said V H comprises an amino acid sequence selected from the group consisting of SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:36.
10. The method of claim 9 , wherein said V L comprises the amino acid sequence of SEQ ID NO:16 and said V H comprises the amino acid sequence of SEQ ID NO:34.
11. The method of claim 1 , wherein said molecule is an antibody or an antigen-binding fragment thereof, or a diabody.
12. The method of claim 11 , wherein said molecule is a diabody.
13. The method of claim 1 , wherein said molecule is a polypeptide.
14. The method of claim 11 , wherein said molecule comprises a variant Fc domain comprising one or more modifications in the Fc domain relative to a wild-type human IgG1 Fc domain, wherein said modification(s) comprise:
(A) one substitution selected from the group consisting of F243L, D270E, R292P, S298N, Y300L, V305I, A330V, and P396L;
(B) two substitutions selected from the group consisting of F243L and P396L; F243L and R292P; and R292P and V305I;
(C) three substitutions selected from the group consisting of F243L, R292P and Y300L; F243L, R292P and V305I; F243L, R292P and P396L; and R292P, V305I and P396L;
(D) four substitutions selected from the group consisting of F243L, R292P, Y300L and P396L; and F243L, R292P, V305I and P396L; or
(E) F243L, R292P, Y300L, V305I and P396L substitutions;
wherein the positions are numbered according to the EU index as in Kabat.
15. The method of claim 14 , wherein said variant Fc domain exhibits an altered effector function as compared to the wild-type Fc domain, wherein said altered effector function is selected from the group consisting of:
(A) enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) function;
(B) enhanced complement-dependent cytotoxicity (CDC) function;
(C) increased binding to an activating FcγR as compared to a wild-type Fc domain;
(D) decreased binding to FcγRIIB as compared to a wild-type Fc domain; and
(E) increased binding to FcγRIIB as compared to a wild-type Fc domain.
16. The method of claim 1 , wherein said subject has a cancer or an autoimmune or immune-mediated inflammatory disease.
17. The method of claim 16 , wherein said subject has an autoimmune or immune-mediated inflammatory disease selected from the group consisting of Crohn's disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, vasculitis, asthma, eczema and atopic dermatitis, fibrosis, graft rejection, graft-versus-host-disease, and inflammatory bowel disease.
18. The method of claim 1 , comprising the further step of administering an additional therapeutic agent with said molecule that binds human BCR complex.
19. The method of claim 18 , wherein said additional therapeutic agent is selected from the group consisting of an anti-angiogenic agent, an anti-neoplastic agent, a chemotherapeutic agent, and a cytotoxic agent.